GlassScriptPhysician profile
Robin Kay Smith
NPI 1104835859
$1,771.01
in general payments reported to CMS, 2019-2025
25 companies · $653 in 2025
The $653 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $50.25 · 2023: $390 · 2024: $678 · 2025: $653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,721.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,720.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $268.93 | 2022-2025 | |
| Lilly USA, LLC | $197.25 | 2023-2024 | Jardiance, Mounjaro |
| Vanda Pharmaceuticals INC. | $164.83 | 2025 | Fanapt |
| Novo Nordisk INC | $151.49 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $135.96 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $111.46 | 2023-2025 | Breztri, Airsupra |
| Axsome Therapeutics, INC. | $80.60 | 2024-2025 | Auvelity |
| Abbott Laboratories | $72.81 | 2023-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $71.60 | 2023-2024 | Cologuard Collection Kit |
| Amgen INC. | $61.64 | 2024-2025 | Repatha, Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $60.74 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $49.05 | 2024 | |
| Astellas Pharma US INC | $47.12 | 2024-2025 | Myrbetriq, Veozah |
| Amneal Pharmaceuticals LLC | $46.39 | 2023 | Lyvispah |
| Pfizer INC. | $44.04 | 2023-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.63 | 2024 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.34 | 2023 | Jardiance |
| Abiomed | $24.14 | 2025 | |
| Janssen Pharmaceuticals, INC | $23.94 | 2023 | Xarelto |
| Phathom Pharmaceuticals, INC. | $18.35 | 2024 | Voquezna |
| Insulet Corporation | $18.07 | 2025 | Omnipod |
| Merck Sharp & Dohme LLC | $17.92 | 2023 | Gardasil 9, Vaxelis, Rotateq |
| Verona Pharma, INC. | $17.24 | 2025 | Ohtuvayre |
| Takeda Pharmaceuticals U.S.A., INC. | $15.76 | 2024 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.71 | 2024 | Trulance, Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.